Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Paroxysmal Nocturnal Hemoglobinuria Pipeline Review, H2 2016 - Research and Markets

Research and Markets
Posted on: 20 Oct 16

Research and Markets has announced the addition of the "Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2016" report to their offering.

Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2016: Paroxysmal Nocturnal Hemoglobinuria pipeline therapeutics constitutes close to 21 molecules, out of which approximately 21 molecules are developed by Companies.

The report "Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2016" outlays comprehensive information on the therapeutics under development for Paroxysmal Nocturnal Hemoglobinuria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, that are being developed by Companies/Universities.

Paroxysmal Nocturnal Hemoglobinuria is a rare disease in which red blood cells break down earlier than normal. Symptoms include abdominal pain, back pain, dark urine, easy bruising or bleeding, headache and shortness of breath. The predisposing factors include age, obesity and hormone therapy. Treatment includes surgery, chemotherapy and radiation therapy.

It also reviews key players involved in therapeutic development for Paroxysmal Nocturnal Hemoglobinuria and features dormant and discontinued projects. Currently, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 4, 11 and 2, respectively.

Key Topics Covered:

  1. Introduction
  2. Paroxysmal Nocturnal Hemoglobinuria Overview
  3. Therapeutics Development
  4. Pipeline Products for Paroxysmal Nocturnal Hemoglobinuria - Overview
  5. Pipeline Products for Paroxysmal Nocturnal Hemoglobinuria - Comparative Analysis
  6. Paroxysmal Nocturnal Hemoglobinuria - Therapeutics under Development by Companies
  7. Paroxysmal Nocturnal Hemoglobinuria - Therapeutics under Investigation by Universities/Institutes
  8. Paroxysmal Nocturnal Hemoglobinuria Products Glance
  9. Late-Stage Products
  10. Clinical-Stage Products
  11. Early-Stage Products
  12. Paroxysmal Nocturnal Hemoglobinuria - Products under Development by Companies
  13. Paroxysmal Nocturnal Hemoglobinuria - Products under Investigation by Universities/Institutes
  14. Paroxysmal Nocturnal Hemoglobinuria - Companies Involved in Therapeutics Development
  • Achillion Pharmaceuticals Inc.
  • Akari Therapeutics Plc
  • Alexion Pharmaceuticals Inc.
  • Alnylam Pharmaceuticals Inc.
  • Amgen Inc.
  • Amyndas Pharmaceuticals LLC
  • Apellis Pharmaceuticals Inc.
  • Epirus Biopharmaceuticals Inc.
  • Novartis AG
  • Omeros Corporation
  • Ra Pharmaceuticals Inc.
  • Regenesance BV
  • The International Biotechnology Center (IBC) Generium

For more information about this report visit http://www.researchandmarkets.com/research/5x7h76/paroxysmal.

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161020006514/en/

Business Wire
www.businesswire.com

Last updated on: 20/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.